Document Detail


Percutaneous treatment of lymphatic malformations.
MedLine Citation:
PMID:  19643255     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The aim of this study is to investigate a new treatment regimen for macrocystic and microcystic lymphatic malformations (LM) of the head and neck. STUDY DESIGN: The study represents a retrospective review of outcomes from new percutaneous treatments for lymphatic malformations. SUBJECTS AND METHODS: Thirty-one patients (age range, 2 days to 51 years of age) underwent percutaneous treatment for LM of the head and neck from 2001 to 2007. The LM involved the orbit, ear, parotid gland, face, and neck. Twenty-seven patients underwent primary treatment of LM; 4 were treated for recurrence after operative resection. Macrocysts (>or=1 cm) were treated with dual-drug chemoablation (sequential intracystic sodium tetradecyl sulfate and ethanol); doxycycline was used for microcysts. Macrocysts and microcysts were treated after complete cyst aspiration with sonographic guidance. Fifty-four macrocysts and 125 microcysts were treated. The goal of treatment was complete cyst ablation documented by sonography or MR imaging. RESULTS: Mean number of treatments was 1.7 per patient; mean number of treatments for macrocysts was 1.1; mean treatments for microcysts was 1.7. Ablation efficacy was 179 of 179 (100%) cysts. Effective cyst ablation achieved effective clinical control with resolution of the external mass appearance. Treatments included massive head and neck mixed LM and cysts surrounding the facial nerve and brachial plexus. Infection occurred in 2 (6%) of 31 patients. No patient experienced postprocedural pain, skin necrosis, neuropathy, skin retraction, or myoglobinuria. CONCLUSION: Percutaneous sclerotherapy provides effective treatment for macrocystic and microcystic LM as primary treatment or for recurrence after surgical resection.
Authors:
William E Shiels; D Richard Kang; James W Murakami; Mark J Hogan; Gregory J Wiet
Related Documents :
20532685 - Response to growth hormone therapy in indian patients.
1326395 - Histologic follow-up of ampullary adenomas in patients with familial adenomatosis coli.
19577475 - Manifestation, management and outcome of subclinical pituitary adenoma apoplexy.
10660025 - Postoperative mri appearance after transsphenoidal pituitary tumor resection.
24618175 - A large italian observational multicentre study on vascular ulcers of the lower limbs (...
16187725 - Clinical utility of portable versus traditional electrodiagnostic testing for diagnosin...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery     Volume:  141     ISSN:  0194-5998     ISO Abbreviation:  Otolaryngol Head Neck Surg     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-31     Completed Date:  2009-09-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8508176     Medline TA:  Otolaryngol Head Neck Surg     Country:  United States    
Other Details:
Languages:  eng     Pagination:  219-24     Citation Subset:  IM    
Affiliation:
Department of Radiology, Nationwide Children's Hospital and The Ohio State University Medical Center, Columbus, Ohio 43205, USA. william.shiels@nationwidechildrens.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Adolescent
Adult
Anti-Bacterial Agents / therapeutic use
Child
Child, Preschool
Cysts / drug therapy*,  pathology
Doxycycline / therapeutic use
Drug Therapy, Combination
Ethanol / administration & dosage,  therapeutic use*
Female
Head / pathology
Humans
Infant
Infant, Newborn
Lymphatic Abnormalities / drug therapy*,  pathology
Male
Middle Aged
Neck / pathology
Recurrence
Retrospective Studies
Risk Assessment
Sclerosing Solutions / administration & dosage,  therapeutic use*
Sclerotherapy / methods*
Severity of Illness Index
Sodium Tetradecyl Sulfate / administration & dosage,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Sclerosing Solutions; 1191-50-0/Sodium Tetradecyl Sulfate; 564-25-0/Doxycycline; 64-17-5/Ethanol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential expression of SKI oncogene protein in hemangiomas.
Next Document:  Partial cricotracheal resection in children: Potential pitfalls and avoidance of complications.